University of Maryland School of Medicine announces Greenebaum family's $5.5 million donation to advance cancer research and patient care at UMGCCC.

Photo of Michael Greenebaum in a suit jacket against a blurred autumn backdrop, paired with a message about legacy and cancer research commitment.

A $5.5M gift from the Marlene and Stewart Greenebaum Family Foundation will accelerate cancer research and care at UMGCCC—supporting innovations like CAR T‑cell therapy for solid tumors and expanding survivorship programs across Maryland.

#MedSky #MedEd #CancerResearch #Oncology #CancerCare

A new preprint, featuring Quantum-Si single-molecule protein sequencing in cancer drug development, is now out on bioRxiv. Congratulations to the researchers at The University of British Columbia and the BC Cancer Research Institute!

Press Release: bit.ly/4240P07

#QSI #CancerResearch #Proteomics

New insights show how immune cells can detect signals from tumors and track them down. The research points to a more targeted future for immunotherapy.

Learn more: med.stanford.edu/news/all-new...

#StanfordMedicine #CancerResearch #Immunotherapy

Improving Reproducibility in Colony Formation Assays Improve reproducibility in adherent and non-adherent clonogenic and soft agar assays by reducing human fatigue and bias. Learn how the GelCount automated colony counter enhances consistency, accuracy,...

What if reproducibility issues in clonogenic assays start with the counting step?

Our latest resource shows how #GelCount reduces subjectivity with standardized detection, digital image archiving, and faster analysis.

#ClonogenicAssay #CancerResearch

www.oxford-optronix.com/resources/im...

CLEAR-PC was recently presented by our Portuguese project partner at an event promoted by the Portuguese League Against Cancer

🌍 Excited to share that the CLEAR-PC project was recently presented in Portugal at an event hosted by the Portuguese League Against Cancer (LPCC) 🎗️.

#CLEARPC #EU4Health #CancerResearch

#CancerResearch Spotlight: Senior author Mandeep Sawhney, MD, BIDMC Division of Gastroenterology, and team found patients prefer EUS for #pancreaticcancer screening, and MRCP for pancreatic cyst surveillance.

These findings support a more patient-centered, individualized screening approach.

Immunotherapy cancer treatment proves promising at Duke University As colon cancer rates among people younger than 50 skyrocket, a new clinical trial that uses immunotherapy, rather than physically demanding chemotherapy, is yielding promising results.Spencer Laird…

As colon cancer rates rise among people under 50, a new clinical trial using immunotherapy instead of chemotherapy is showing promising results. Researchers say the approach can reduce side effects while helping the immune system target cancer cells.
#CancerResearch @duke-university.bsky.social

The Lancet Regional Health Americas journal cover picture

🌍 𝐍𝐞𝐰 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐨𝐧 𝐬𝐞𝐱 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞𝐬 𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐦𝐨𝐫𝐭𝐚𝐥𝐢𝐭𝐲 𝐢𝐧 𝐂𝐨𝐥𝐨𝐦𝐛𝐢𝐚 (1980–2023)

Co‑authored by Associate Professor Dr Rocco Friebel.

🔗 Read more: bit.ly/3OE022T

#GlobalHealth #Mortality #CancerResearch #Disparities

Revolution Medicines Rises on Daraxonrasib Data Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12, 2026).

Revolution Medicines Rises on Daraxonrasib Data: Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12,… 👈 Read full analysis #RevolutionMedicines #Daraxonrasib #PancreaticCancer #CancerResearch #Biotech

Job Alert

Head of an Independent Junior Research Group in Translational Gynecologic Cancer Research

Deadline: 2026-05-17 
Location: Germany - Heidelberg

www.academiceurope.com/ads/head-of-...

#hiring #CancerResearch #GynecologicCancer #LifeSciences #ResearchLeadership #medicalscience #medicine

Mini tumours grown from a bowel cancer.

🔬 ICR and @rcsi.bsky.social scientists have developed a new way to determine which patients will respond best to #BowelCancer treatment – potentially sparing thousands of patients from treatments that won’t work for them.

Read more in our🧵

#AI #ArtificialIntelligence #CancerResearch

First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know Revolution Medicines shared Phase III clinical trial results for a pill called daraxonrasib in patients with previously treated metastatic pancreatic cancer.

A new pancreatic cancer pill has nearly doubled survival in trials, offering real hope in one of the toughest cancers to treat. This is the kind of progress patients have been waiting for. #PancreaticCancer #CancerResearch #Oncology #TCSC
pancan.org/news/first-r...

New positions in the lab!

Our project on chemoresistance and genome instability has been funded by German Cancer Aid - Krebshilfe_Bonn

We are hiring:
🔬 PhD student
🔬 Postdoc

Focus: DNA repair, mutagenesis & functional genomics.

Get in touch!
#PhD #Postdoc #CancerResearch

Terry Fox on Canada’s FIVE DOLLAR BILL.

FINALLY! A modern day Canadian hero we can all relate to. #Courage #TerryFox #CancerResearch #MarathonOfHope #Canada #Hero

Terry Fox is a true Canadian hero, adored by all Canadians for his courage and selflessness. He always knew his marathon was to help others beat cancer. He earned his place on Canadian currency.

#CdnPoli #TerryFox #CancerResearch #CancerSucks #Canada

Revolution Medicines' pancreatic cancer drug boosts survival in late-stage trial, firm seen as takeover target #Biotech #CancerResearch

🚨 Revolution Medicines’ pancreatic cancer drug doubles survival in Phase 3 trial vs chemo. $RVMD #Biotech #CancerResearch

Check out this webinar on-demand:

Experts from Dana-Farber Cancer Institute, Arcitecta, and Spectra Logic recently discussed best practices for managing rapidly growing research data.

bit.ly/47Isd74 #LifeSciences #DataManagement #CancerResearch

Cancer treatment is evolving fast, but refinement matters as much as discovery. Better selection, better sequencing and better tolerability can change lives. #CancerResearch #PrecisionOncology #TCSC

New trial results show that adding Tukysa to maintenance therapy can delay cancer growth by nearly 9 months compared to the standard of care.

Read the full breakdown of the HER2CLIMB-05 trial: https://bit.ly/3MNahAW

#BreastCancer #CancerResearch

Original post on mastodon.social

From Oxford Academic Journal of the National Cancer Institute:
“ Based on 2 cohorts of health professionals, our findings suggest that the increased risk of CRC associated with alcohol intake is driven mainly by total quantity and remote intake. Former drinkers did not experience an immediate […]

A "new contender" (and a client) enters the #TcellEngager and #Bispecific #ADC arena with a novel, conditionally activated TCE strategy called #BiTAC. Interested to hear people’s thoughts on this one...

#AACR2026 #CancerResearch #Immunotherapy

GSK Follows Oncology Rivals’ Playbook in Search of Growth GSK is launching FIVE late-stage cancer trials at once—because “wait and see” is so last season. Luke Miels is playing oncology on hard mode. #GSK #CancerResearch #PharmaNews

GSK is launching FIVE late-stage cancer trials at once—because “wait and see” is so last season. Luke Miels is playing oncology on hard mode. #GSK #CancerResearch #PharmaNews

Download Karan Kavach
www.karankavach.com

Revolution Medicines Rises on Daraxonrasib Data Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release Apr 12, 2026).

Revolution Medicines Rises on Daraxonrasib Data: Revolution shares jumped ~46% on Apr 13, 2026 after daraxonrasib showed a 44% ORR in an 18-patient pancreatic cohort (Revolution press release… 👈 Read full analysis #RevolutionMedicines #Daraxonrasib #PancreaticCancer #CancerResearch #Pharmaceuticals

#Cancer #Treatment #Webcast #Virtual #April #Research #MinimalResidualDisease #DalhousieU #Leukemia #Lymphoma #CancerResearch #CancerCare #LLSCanada #PrecisionMedicine

#Cancer #Treatment #Webcast #Virtual #Genetics #April #Research #VCHhealthcare #Leukemia #Lymphoma #CancerResearch #CancerCare #LLSCanada #PrecisionMedicine

AI to predict how bowel cancer patients will respond to new NHS drug PhenMap tool could spare thousands of patients from treatment that would be ineffective for them

AI tool PhenMap predicts responses to new bowel cancer drug, sparing many patients from ineffective treatments.
www.theguardian.com/society/2026/apr/13/ai-b...
#AI #MachineLearning #CancerResearch #HealthTech #AIApplications

Revolution Medicines' Daraxonrasib Wins Phase 3 Trial Revolution Medicines reported Phase 3 success for daraxonrasib on Apr 13, 2026, affecting ~64,000 U.S. pancreatic cancer cases/year and a disease with ~12% 5-year survival.

Revolution Medicines' Daraxonrasib Wins Phase 3 Trial: Revolution Medicines reported Phase 3 success for daraxonrasib on Apr 13, 2026, affecting ~64,000 U.S. pancreatic cancer cases/year and a… 👈 Read full analysis #RevolutionMedicines #Daraxonrasib #Phase3Trial #PancreaticCancer #CancerResearch

Lilly's Jaypirca Improves Survival in CLL Lilly reported a 26% reduction in mortality risk (HR 0.74) for Jaypirca in CLL on Apr 13, 2026, per Investing.com; implications for LLY's oncology franchise and BTK pricing are immediate.

Lilly's Jaypirca Improves Survival in CLL: Lilly reported a 26% reduction in mortality risk (HR 0.74) for Jaypirca in CLL on Apr 13, 2026, per Investing.com; implications for LLY's oncology franchise and BTK pricing are immediate. 👈 Read full analysis #Lilly #Jaypirca #CLL #Oncology #CancerResearch

Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma
fondazionebonadonna.org/en/a-compari...
#FondazioneBonadonna #Oncology #CancerResearch